J&J Not Sweating Remicade Biosimilar Approval
This article was originally published in The Pink Sheet Daily
The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.
You may also be interested in...
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.